---
title: "Cel-Sci Forms Multikine Commercialization Partnership in Middle East"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286482219.md"
description: "Cel-Sci has formed a strategic partnership with Amarox for the commercialization of its cancer immunotherapy, Multikine, in Saudi Arabia, with potential expansion to the Gulf Cooperation Council region. This partnership aims to enhance regulatory affairs and marketing efforts. However, Spark's analysis rates CVM stock as Neutral due to weak financial performance and a strong downtrend in technicals. Cel-Sci focuses on developing immunotherapy treatments for cancer, particularly Multikine for head and neck cancer, targeting international markets through partnerships."
datetime: "2026-05-14T23:34:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286482219.md)
  - [en](https://longbridge.com/en/news/286482219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286482219.md)
---

# Cel-Sci Forms Multikine Commercialization Partnership in Middle East

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Cel-Sci ( (CVM) ) has shared an update.

On May 11, 2026, Cel-Sci announced a strategic partnership, distribution, and revenue-sharing agreement with Amarox covering regulatory affairs, marketing, and potential commercialization of its cancer immunotherapy Multikine for head and neck cancer in Saudi Arabia. The deal may be extended to include the wider Gulf Cooperation Council region, signaling Cel-Sci’s intent to expand its geographic footprint and build a commercial pathway for Multikine in key Middle Eastern markets.

**Spark’s Take on CVM Stock**

According to Spark, TipRanks’ AI Analyst, CVM is a Neutral.

The score is driven primarily by weak financial performance (pre-revenue losses, ongoing cash burn, and elevated balance sheet/cash flow volatility). Technicals also weigh on the score due to a strong downtrend, partially offset by oversold indicators. Valuation is constrained by negative earnings and the absence of a dividend.

To see Spark’s full report on CVM stock, click here.

**More about Cel-Sci**

Cel-Sci is a biotechnology company focused on developing immunotherapy treatments for cancer, including its lead product candidate Multikine (Leukocyte Interleukin, Injection) for head and neck cancer. The company targets international markets through partnerships to advance regulatory approvals, marketing, and potential commercialization of its therapies.

**Average Trading Volume:** 226,160

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $10.06M

### Related Stocks

- [CVM.US](https://longbridge.com/en/quote/CVM.US.md)

## Related News & Research

- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [Avalere Health launches ‘Within Reach’, a new oncology anthology about what it really means to navigate cancer access, treatment, and care](https://longbridge.com/en/news/287075968.md)
- [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md)